Clinical Trial Update: Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) [Phase 2, Phase 3]

View source ↗

Summary

CTAP101 was evaluated in patients with chronic kidney disease and secondary hyperparathyroidism in Phase 2/3 safety and efficacy trials; the studies are complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• CTAP101

Snippet

Sponsor: OPKO Health, Inc. | Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2016-08-25